Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bolaget.

Datum Källa Rubrik Typ Alternativ
2021-11-25 Lipidor Lipidor publishes interim report for period 1 January - 30 September and Q3 2021 Rapporter Ladda ner | Visa Stäng
2021-11-25 Lipidor Lipidor publicerar delårsrapport för perioden 1 januari - 30 september och det tredje kvartalet 2021 Rapporter Ladda ner | Visa Stäng
2021-10-29 Lipidor Lipidor submits new patent application and expands collaboration with Cannassure using Lipidor's AKVANO[®] technology for medicinal cannabis products Pressreleaser Ladda ner | Visa Stäng
2021-10-29 Lipidor Lipidor lämnar in en ny patentansökan och utökar samarbetet med Cannassure om medicinska cannabisprodukter baserade på Lipidors AKVANO[®]-teknologi Pressreleaser Ladda ner | Visa Stäng
2021-10-19 Lipidor Optionsinnehavare i Lipidor utnyttjar samtliga teckningsoptioner i incitamentsprogrammet 2018/2021 Pressreleaser Ladda ner | Visa Stäng
2021-10-19 Lipidor Warrant holders exercise all warrants in Lipidor's incentive program 2018/2021 Pressreleaser Ladda ner | Visa Stäng
2021-09-30 Lipidor BioStock: Lipidors fas III-studie är godkänd och startredo Pressreleaser Visa Stäng
2021-09-27 Lipidor Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis Pressreleaser Ladda ner | Visa Stäng
2021-09-27 Lipidor Lipidor meddelar godkännande för studiestart av klinisk Fas III-studie av psoriasiskandidaten AKP02 Pressreleaser Ladda ner | Visa Stäng
2021-08-24 Lipidor Lipidor publicerar delårsrapport för H1 2021 Rapporter Ladda ner | Visa Stäng
2021-08-24 Lipidor Lipidor publishes interim report for H1 2021 Rapporter Ladda ner | Visa Stäng
Rapporter | 24 Aug 2021 | Lipidor

Lipidor publishes interim report for H1 2021

Summary of the interim report – second quarter 2021

Lipidor has had an intense first half year with success in many areas. At the beginning of the year, we signed a license agreement with Cannassure Therapeutics (for topical medical cannabis products based on Lipidor’s AKVANO® technology), we submitted an application during the first quarter for the start of the Phase III study for our combination drug for psoriasis (AKP02), and our subsidiary Emollivet received a grant from Vinnova to prepare for the launch of veterinary drugs.

Second quarter (Apr-Jun) 2021 Reporting period (Jan-Jun) 2021
Net sales 2 KSEK (461) Net sales 104 tkr (461)
Operating income -7 470 KSEK ( Operating income -12 732 tkr (
-2 876) -5 800)
Result per share prior to and Result per share prior to and
after dilution -0,26 SEK ( after dilution -0,45 SEK (
-0,12) -0,25)

Significant events during the second quarter (Jan-Mar)

  • On 22[nd] April Lipidor provided an update on the planned Phase lll study of the company’s drug candidate AKP02 for the treatment of psoriasis.
  • On 23[rd] April it was announced that Lipidor’s subsidiary Emollivet AB had taken the next step towards launching and was to receive funding of SEK 300,000 from Vinnova.

Significant events during the reporting period

  • On 18[th] January, it was announced that Lipidor had entered into an exclusive agreement with Cannassure Therapeutics Ltd in Israel for medical cannabis products based on Lipidor’s AKVANO® technology. Lipidor will receive double-digit royalties from upcoming product sales as well as a milestone payment for a certain sales volume achieved up to a maximum of €350,000 EUR.

Significant events after the reporting period

  • On 1[st] July we announced that Lipidor has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries. The total potential value of this agreement is up to MEUR 70.

Selected financial data

000’s 2021 2020 2021 2020 2020
apr-jun apr-jun jan-jun jan-jun jan-dec
Net sales 2 461 104 461 620
Operating income -7 470 -2 876 -12 732 -5 800 -16 264
Income after tax -7 470 -2 876 -12 732 -5 800 -16 204
Total assets 55 443 22 545 55 443 22 545 65 877
Cash flow for the -6 187 -3 223 -11 177 -2 970 37 190
period
Cash flow per share -0.22 -0.14 -0.39 -0.13 1.51
(SEK)
Cash 53 126 20 920 53 126 20 920 64 303
Result per share -0.26 -0.12 -0.45 -0.25 -0.66
prior to dilution
(SEK)
Result per share -0.26 -0.12 -0.45 -0.25 -0.66
after dilution (SEK)
Shareholder’s equity 1.79 0.89 1.79 0.89 2.24
per share (SEK)
Equity ratio, % 91.85 93.26 91.85 93.26 96.63

Lipidor in Brief

Lipidor AB, Org. Nr. 556779-7500 is a Swedish limited company based in Stockholm. The company address is: Lipidor AB, Fogdevreten 2, 175 21 Solna.

Lipidor is a drug development company with a pipeline of drug development projects in the preclinical and clinical phase. The company develops drugs for the treatment of skin diseases such as psoriasis, bacterial skin infections and atopic dermatitis.

In 2019, the subsidiary Emollivet AB was formed, with a focus on veterinary care products based on AKVANO.

 

Statement from Lipidor’s CEO

The first six months of the year were intense with several important advancements for Lipidor. Great focus and intense efforts were devoted to the negotiations regarding an agreement for future commercialization of our two initial pharmaceutical candidates for psoriasis, AKP01 and AKP02. The outcome was announced on July 1st when we reported that Lipidor had signed an exclusive license agreement with RELIFE S.r.l., a part of the Menarini group, which has strong presence in both Europe and as well in the global market. The deal marks an important milestone for Lipidor, and we look forward to a successful commercial cooperation.

The agreement grants exclusive rights to register, promote, distribute, and market in EU, Turkey, UK, Switzerland, CIS (independent nations commonwealth of former Soviet states), and Balkan countries. The agreement stipulates that future development and related costs for AKP01 and AKP02, subsequent to concluded phase lll-study, in essence are assumed by our new partner. Lipidor will contribute its expertise and knowledge in specific issues related to the pharmaceutical candidates.

Lipidor filed a study application initiation with AKP02 to the Indian authorities during the second quarter. We expect to be able to present results from the study during the first half of 2022. Our partner is Aurena Laboratories, one of Lipidor’s two major industrial shareholders, which will manage commercial production of the products. Market launch by RELIFE within the agreement is expected during the second half of 2013.

Licensing in other markets

We conducted an extensive evaluation process regarding licensing partners, and our choice fell Menarini Group which is a solid partner with distribution capacity and resilience in order to establish the pending products in the contracted markets. We now continue our efforts in evaluating licensing in other markets along with Menarini Group as well as other potential partners.

External validation of AKVANO®

External validation provides a vitamin-injection for us at Lipidor. That supports us in our vision to establish AKVANO® as a leading development platform in development of topical pharmaceuticals, and in our ambition to improve every-day life for millions of individuals with skin diseases.

Early this year we entered into an exclusive licensing agreement with Cannassure Therapeutics for topical medicinal cannabis products based on Lipidor’s AKVANO®-technology. The agreement is an important external validation of our patented formulating platform and it demonstrates that cannabinoids also may be incorporated in AKVANO®.

During the second quarter our subsidiary Emollivet AB received a grant from Sweden’s innovation authority, Vinnova. Emollivet develops animal-care products based on AKVANO®. This financing will be used for a project in which Emollivet by interaction with animal owners and entities in the animal care market, gathers support ahead of the pending launch of animal care products.

Eventful fall

Lipidor’s AKVANO® technology currently has both medicinal proof-of-concept (the phase lll-study in AKP01) and commercial proof-of-concept (license agreements with Cannassure and Menarini). Along with existing liquidity and milestone payments, including among others a signing fee, the company’s operations under current plans are financed for the foreseeable future. Furthermore, we have the reserves to ramp up speed in both our preclinical, and clinical development. Our ambition is to develop additional pharmaceutical candidates based on AKVANO in areas estimated to indicate strong demand for improved products. Our ambition is to enter into additional license agreements over the coming years and to generate a portfolio generating income from several products.

I am expectant and optimistic for Lipidor’s future growth. In the near future, I look forward to an eventful fall and, among other, updates regarding the cooperation with Cannassure, developments within animal care in Emollivet, initiation of the phase lll-study in AKP02, and updates regarding Lipidor’s clinical programs.

Stockholm, August 24, 2021

Ola Holmlund

CEO

 

Financial Calendar

Interim report January – September                   25[th] November 2021

Year-end report January – December 2021                    17[th] November 2021

Interim report January – March 2022                  5[th] May 2022

Information

The information was provided for publication through the office of Lipidor’s CEO on 24[th] August 2021 at 8.30am (CEST).

2021-07-06 Lipidor Sommarbrev från Lipidor Pressreleaser Ladda ner | Visa Stäng
2021-07-06 Lipidor Summer letter from Lipidor Pressreleaser Ladda ner | Visa Stäng
2021-07-01 Lipidor Lipidor licensavtal ger Menarini Group-bolaget RELIFE Srl exklusiva rättigheter att registrera, marknadsföra, distribuera och sälja två nya psoriasis läkemedelskandidater med potentiellt värde 70 MEUR Pressreleaser Ladda ner | Visa Stäng
2021-07-01 Lipidor Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70 Pressreleaser Ladda ner | Visa Stäng
2021-06-08 Lipidor Bulletin from the Extraordinary General Meeting of Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-06-08 Lipidor Kommuniké från extra bolagsstämma i Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-06-08 Lipidor Kommuniké från årsstämma i Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-06-08 Lipidor Bulletin from the annual general meeting of Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-05-24 Lipidor KALLELSE TILL EXTRA BOLAGSSTÄMMA i Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-05-24 Lipidor Lipidor: NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-05-07 Lipidor KALLELSE TILL ÅRSSTÄMMA i Lipidor AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-05-07 Lipidor Lipidor: NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-05-06 Lipidor Lipidor publishes interim report for Q1 2021 Rapporter Ladda ner | Visa Stäng
2021-05-06 Lipidor Lipidor publicerar delårsrapport för Q1 2021 Rapporter Ladda ner | Visa Stäng
2021-04-23 Lipidor Lipidor publishes annual report for 2020 Rapporter Ladda ner | Visa Stäng
2021-04-23 Lipidor Lipidor publicerar årsredovisning för 2020 Rapporter Ladda ner | Visa Stäng
2021-04-23 Lipidor Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova Pressreleaser Ladda ner | Visa Stäng
2021-04-23 Lipidor Lipidors dotterföretag Emollivet tar nästa steg mot lansering och finansieras av Vinnova Pressreleaser Ladda ner | Visa Stäng
2021-04-22 Lipidor Lipidor - uppdatering om bolagets kliniska Fas III-studie med läkemedelskandidaten AKP02 för behandling av psoriasis Pressreleaser Ladda ner | Visa Stäng
2021-04-22 Lipidor Lipidor - update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis Pressreleaser Ladda ner | Visa Stäng
2021-03-04 Lipidor Lipidor presenterar på Erik Penser Banks Bolagsdag den 11 mars Pressreleaser Ladda ner | Visa Stäng
2021-02-23 Lipidor Lipidor AB (publ) offentliggör bokslutskommuniké för 2020 Rapporter Ladda ner | Visa Stäng
2021-02-23 Lipidor Lipidor AB (publ) publishes year-end report for 2020 Rapporter Ladda ner | Visa Stäng
2021-01-18 Lipidor Lipidor and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO[®] technology Pressreleaser Ladda ner | Visa Stäng
2021-01-18 Lipidor Lipidor och Cannassure tecknar exklusivt licensavtal avseende topikala medicinska cannabisprodukter baserade på Lipidors AKVANO[®]-teknologi Pressreleaser Ladda ner | Visa Stäng
2020-12-16 Lipidor Lipidor tecknar samarbetsavtal med kontraktstillverkare för att kunna erbjuda licenstagare möjlighet till GMP- produktion Pressreleaser Ladda ner | Visa Stäng
2020-12-16 Lipidor Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production Pressreleaser Ladda ner | Visa Stäng
2020-11-27 Lipidor Lipidor presents Nomination Committee Pressreleaser Ladda ner | Visa Stäng
2020-11-27 Lipidor Lipidor presenterar valberedningen Pressreleaser Ladda ner | Visa Stäng
2020-11-19 Lipidor Lipidor publicerar delårsrapport för Q3 2020 Rapporter Ladda ner | Visa Stäng
2020-11-19 Lipidor Lipidor publishes interim report for Q3 2020 Rapporter Ladda ner | Visa Stäng
2020-11-11 Lipidor Rättelse av pressmeddelande "Lipidor tillförs cirka 19,9 MSEK till följd av utnyttjade teckningsoptioner av serie TO1 2019" Pressreleaser Ladda ner | Visa Stäng
2020-11-04 Lipidor Lipidor tillförs cirka 19,9 MSEK till följd av utnyttjade teckningsoptioner av serie TO1 2019 Pressreleaser Ladda ner | Visa Stäng
2020-10-14 Lipidor Teckningskurs fastställd för Lipidors teckningsoption av serie TO1 2019 Pressreleaser Ladda ner | Visa Stäng
2020-10-07 Lipidor Lipidor byter Certified Adviser till Erik Penser Bank AB Pressreleaser Ladda ner | Visa Stäng
2020-10-01 Lipidor Lipidor strengthens management through strategic hire Pressreleaser Ladda ner | Visa Stäng
2020-10-01 Lipidor Lipidor förstärker ledningen genom en strategisk rekrytering Pressreleaser Ladda ner | Visa Stäng
2020-09-30 Lipidor Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO® technology Pressreleaser Ladda ner | Visa Stäng
2020-09-30 Lipidor Lipidor meddelar positivt utfall av genomförbarhetsstudien för utveckling av topikala medicinska cannabisprodukter baserade på bolagets AKVANO®-teknologi Pressreleaser Ladda ner | Visa Stäng
2020-09-11 Lipidor Lipidor tillförs 35,0 MSEK genom riktad nyemission om 2,8 miljoner aktier Pressreleaser Ladda ner | Visa Stäng
2020-09-10 Lipidor Lipidor utreder förutsättningarna för att genomföra en riktad nyemission Pressreleaser Ladda ner | Visa Stäng
2020-08-18 Lipidor Correction: Lipidor publishes interim report for H1 2020 Rapporter Ladda ner | Visa Stäng
2020-08-18 Lipidor Lipidor publishes interim report for H1 2020 Rapporter Ladda ner | Visa Stäng
2020-08-18 Lipidor Lipidor publicerar delårsrapport för H1 2020 Rapporter Ladda ner | Visa Stäng
2020-08-11 Lipidor Resolutions from Lipidor's Extraordinary General Meeting Pressreleaser Ladda ner | Visa Stäng
2020-08-11 Lipidor Kommuniké från Lipidors extra bolagsstämma Pressreleaser Ladda ner | Visa Stäng
2020-07-10 Lipidor Lipidor tecknar avtal för leverans av kliniskt prövningsmaterial för Fas III studien med AKP02 Pressreleaser Ladda ner | Visa Stäng
2020-07-07 Lipidor Lipidor signs agreement with CRO for implementation of Phase III clinical study of drug candidate AKP-02 against Psoriasis Pressreleaser Ladda ner | Visa Stäng
2020-07-07 Lipidor Lipidor tecknar avtal med CRO för genomförande av klinisk Fas III studie avseende läkemedelskandidaten AKP-02 mot Psoriasis Pressreleaser Ladda ner | Visa Stäng
2020-07-07 Lipidor Lipidor AB (publ) announces subsidiary Emollivet AB's recruitment of Stina Linge as CEO Pressreleaser Ladda ner | Visa Stäng
2020-07-07 Lipidor Lipidor AB (publ) meddelar att dotterföretaget Emollivet AB rekryterat Stina Linge som VD Pressreleaser Ladda ner | Visa Stäng
2020-06-30 Lipidor Lipidor: KALLELSE TILL EXTRA BOLAGSSTÄMMA i LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-06-30 Lipidor Lipidor: NOTICE OF EXTRAORDINARY GENERAL MEETING OF LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-06-30 Lipidor Lipidor AB (publ) formalizes relationship with subsidiary Emollivet AB through license agreement and proposes financing of subsidiary Pressreleaser Ladda ner | Visa Stäng
2020-06-30 Lipidor Lipidor AB (publ) formaliserar relationen med dotterföretaget Emollivet AB genom licensavtal och föreslår finansiering av dotterföretaget Pressreleaser Ladda ner | Visa Stäng
2020-06-11 Lipidor Lipidor: Resolutions from Annual General Meeting, 11 June 2020 Pressreleaser Ladda ner | Visa Stäng
2020-06-11 Lipidor Kommuniké från årsstämma i Lipidor AB den 11 juni 2020 Pressreleaser Ladda ner | Visa Stäng
2020-05-19 Lipidor Lipidor publicerar delårsrapport för Q1 2020 Rapporter Ladda ner | Visa Stäng
2020-05-19 Lipidor Lipidor publishes interim report for Q1 2020 Rapporter Ladda ner | Visa Stäng
2020-05-12 Lipidor Lipidor publishes annual report for 2019 Rapporter Ladda ner | Visa Stäng
2020-05-12 Lipidor Lipidor publicerar årsredovisning för 2019 Rapporter Ladda ner | Visa Stäng
2020-05-11 Lipidor Lipidor: NOTICE OF ANNUAL GENERAL MEETING OF LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-05-11 Lipidor Lipidor: KALLELSE TILL ÅRSSTÄMMA I LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-05-07 Lipidor Lipidor lämnar uppdaterad projektplan - initierar fas III studie avseende AKP02 i egen regi Pressreleaser Ladda ner | Visa Stäng
2020-05-07 Lipidor Lipidor presents updated project plan - initiates Phase III study of AKP02 in-house Pressreleaser Ladda ner | Visa Stäng
2020-04-28 Lipidor Stor efterfrågan på Skin Disinfection Spray från Aurena Laboratories i samarbete med Lipidor - snart tillgänglig även hos Apotea Pressreleaser Ladda ner | Visa Stäng
2020-03-04 Lipidor Ny desinfektionsspray från Lipidor och Aurena Laboratories Pressreleaser Ladda ner | Visa Stäng
2020-03-04 Lipidor New disinfection spray from Lipidor and Aurena Laboratories Pressreleaser Ladda ner | Visa Stäng
2020-02-25 Lipidor Lipidor AB re-publishes year-end report for 2019 Rapporter Ladda ner | Visa Stäng
2020-02-25 Lipidor Lipidor AB om-publicerar bokslutskommunikén för 2019 Rapporter Ladda ner | Visa Stäng
2020-02-24 Lipidor Lipidor AB (publ) offentliggör bokslutskommunikén för 2019 Rapporter Ladda ner | Visa Stäng
2020-01-31 Lipidor BioStock: Lipidors vd om studieframgången i fas III Pressreleaser Visa Stäng
2020-01-24 Lipidor Lipidor meddelar idag positiva resultat från bolagets kliniska fas III-studie av kalcipotriolspray (AKP01) mot psoriasis Pressreleaser Ladda ner | Visa Stäng
2020-01-24 Lipidor Lipidor announces positive topline results of AKP01 Phase III clinical study using calcipotriol spray against psoriasis Pressreleaser Ladda ner | Visa Stäng
2020-01-02 Lipidor Lipidor AB (publ): KK-stiftelsen finansierar samverkansprojekt för studier av hur läkemedelsformuleringar påverkar hudbarriären Pressreleaser Ladda ner | Visa Stäng
2019-12-17 Lipidor Lipidor AB (publ) uppdaterar tidplan för resultat från pågående fas III-studie - marginell förskjutning av resultatrapportering Pressreleaser Ladda ner | Visa Stäng
2019-12-10 Lipidor Lipidor (Nasdaq First North: LIPI) och Cannassure (TASE:CSURE) ingår avtal om genomförbarhetsstudie och option till licens för utveckling och försäljning av topikala medicinska cannabisprodukter Pressreleaser Ladda ner | Visa Stäng
2019-12-10 Lipidor Lipidor (Nasdaq First North: LIPI) and Cannassure (TASE:CSURE) enter a feasibility study and licence option agreement for development and sales of topical medical cannabis products Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

9 Feb 2021 | Bokslutskommuniké 2020
23 Feb 2021 | Bokslutskommuniké 2020
6 May 2021 | Kvartalsrapport 2021-Q1
8 Jun 2021 | Årsstämma 2020
8 Jun 2021 | Extrastämma 2021
9 Jun 2021 | Årligutdelning
24 Aug 2021 | Kvartalsrapport 2021-Q2
17 Nov 2021 | Kvartalsrapport 2021-Q3
25 Nov 2021 | Kvartalsrapport 2021-Q3
23 Feb 2022 | Bokslutskommuniké 2021
5 May 2022 | Kvartalsrapport 2022-Q1
24 Aug 2022 | Kvartalsrapport 2022-Q2
23 Nov 2022 | Kvartalsrapport 2022-Q3

ca.penser.se använder cookies för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder cookies. Vad är cookies?

Jag godkänner